Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.PURPOSE
 The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.


 Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.


 She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab.  The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.


 To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.
alemtuzumab
Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.PURPOSE

multiple sclerosis-associated uveitis
Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.PURPOSE
 The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.


 Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.


 She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab.  The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.


 To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.
alemtuzumab
Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.PURPOSE
 The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab.


 Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS.


 She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab.  The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission.


 To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.
alemtuzumab